By Mill Chart
Last update: Dec 1, 2023
Our stock screener has singled out NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) as an attractive growth opportunity. NASDAQ:NBIX is demonstrating remarkable growth potential while maintaining strong financial indicators, making it a reasonably priced option. We'll explore this further.
ChartMill employs its own Growth Rating system for all stocks. This score, ranging from 0 to 10, is derived by evaluating different growth factors, such as EPS and revenue growth, taking into account both past performance and future projections. NASDAQ:NBIX has earned a 9 for growth:
To assess a stock's valuation, ChartMill utilizes a Valuation Rating on a scale of 0 to 10. This comprehensive assessment considers various valuation aspects, comparing price to earnings and cash flows, while factoring in profitability and growth. NASDAQ:NBIX has achieved a 6 out of 10:
ChartMill utilizes a Health Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of liquidity and solvency ratios, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 7 out of 10:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NASDAQ:NBIX has earned a 8 out of 10:
Every day, new Affordable Growth stocks can be found on ChartMill in our Affordable Growth screener.
Our latest full fundamental report of NBIX contains the most current fundamental analsysis.
This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.
NEUROCRINE BIOSCIENCES INC
NASDAQ:NBIX (4/26/2024, 7:05:57 PM)
After market: 135.99 0 (0%)135.99
-1.77 (-1.28%)
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of WHAT THE C@H?!, an educational initiative that aims to close the gap...
The economy is looking very strong and the biotech industry even more so, thus consider these top three stocks for strong profits.
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the first patient has been randomized for its Phase 2 clinical study to...
/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 clinical study to evaluate the safety, tolerability,...
DexCom, Blackstone and Royal Caribbean head this list of five stocks.
On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.